Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche MS drug Ocrevus...

    Roche MS drug Ocrevus wins European panel backing

    Written by Ruby Khatun Khatun Published On 2017-11-13T10:02:24+05:30  |  Updated On 18 Aug 2021 3:32 PM IST

    ZURICH: Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for nearly $1 billion in sales in 2017 after winning U.S. regulators' go-ahead earlier this year.


    Ocrevus got a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating adult patients with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).



    Final approval falls to the European Commission, but it generally follows the CHMP recommendation.

    Ocrevus, which racked up sales of 500 million Swiss francs ($503 million) in the first nine months of 2017, is seen generating revenue of more than $4 billion a year by 2022, according to a Reuters survey of analyst estimates.


    Roche's drug is pivotal to the Basel-based drugmaker's strategy of bringing new drugs to market to replace older medicines whose sales are declining now that they are going off-patent.


    "We are pleased that the CHMP has recognized the clinical significance of the Ocrevus data, particularly for people living with primary progressive MS ... that currently has no approved treatments in Europe," said Sandra Horning, Roche's chief medical officer.


    Roche's trio of Herceptin, Avastin and MabThera account for more than $20 billion in annual sales, but competition from cheaper biosimilar copies has already begun eroding sales of some of the medicines.


    For rival Biogen, which co-developed Ocrevus, Roche's drug is a double-edged sword.


    Roche must pay its U.S. partner a royalty of up to 24 percent on Ocrevus's U.S. sales and a 3 percent royalty on sales outside the United States. But Ocrevus is seen eating significantly into Biogen's Tecfidera MS drug, which had nearly $4 billion in annual sales in 2016.


    Ocrevus's continued headway with European regulators is particularly important, given other drugs in Roche's pipeline have had mixed results in recent months.


    In September, a pair of promising medicines, Zelboraf against advanced skin cancer and lampalizumab against vision loss, failed in late-stage trials.


    And while Roche's Tecentriq immunotherapy won EU approval in September for advanced lung and bladder cancer, it failed in a study against bladder cancer compared to chemotherapy earlier this year and has since lost market share.


    Roche Chief Executive Severin Schwan has stuck to expectations his company's sales will continue to grow on the strength of new medicines like Ocrevus.




    (Reporting by John Miller; Editing by Mark Potter)



    AvastinBiogenCHMPEuropean CommissionEuropean panelHerceptinLampalizumabMabTheraMS drugmultiple sclerosisOcrevusprimary progressive multiple sclerosisrecommendationrelapsing multiple sclerosisRocheSandra Horningskin cancerTecfideravision lossZelboraf
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok